SINO BIOPHARM (01177): LM-302 "CLDN18.2 ADC" Included in Breakthrough Therapy Drug Program

Stock News
08/19

SINO BIOPHARM (01177) announced that LM-302 "CLDN18.2 ADC," an innovative drug independently developed by its wholly-owned subsidiary Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. (Lixin Pharmaceutical), has been included in the Breakthrough Therapy Drug (BTD) program by China's Center for Drug Evaluation (CDE) of the National Medical Products Administration. The drug is intended for first-line treatment of CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in combination with PD-1 monoclonal antibody.

LM-302 is a potential first-in-class antibody-drug conjugate (ADC) targeting CLDN18.2. Clinical efficacy has been observed in patients with gastric cancer, pancreatic cancer, and biliary tract cancer, with clinical benefits also seen in patients with low Claudin 18.2 expression and low PD-L1 expression.

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Lixin Pharmaceutical presented the latest research data on LM-302 combined with PD-1 monoclonal antibody for gastric cancer treatment. Among 41 evaluable patients, the objective response rate (ORR) was 65.9% and the disease control rate (DCR) was 85.4%. In 32 patients with CLDN18.2 ≥25%, the ORR was 71.9% and DCR was 96.9%. The study results demonstrated that the LM-302 combination regimen showed favorable anti-tumor activity with manageable safety profile in CLDN18.2-positive patients.

LM-302 is currently undergoing Phase III clinical trials in China for the treatment of CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma that has progressed after second-line or later systemic treatment.

The inclusion in the breakthrough therapy drug program is expected to accelerate LM-302's market approval process, bringing innovative treatment options to more CLDN18.2-positive gastric cancer patients at an earlier stage.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10